Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Archive ouverte

Peters, S. | Pujol, J.-L. | Dafni, U. | Dómine, M. | Popat, S. | Reck, M. | Andrade, J. | Becker, A. | Moro-Sibilot, D. | Curioni-Fontecedro, A. | Molinier, O. | Nackaerts, K. | Insa Mollá, A. | Gervais, R. | López Vivanco, G. | Madelaine, J. | Mazieres, J. | Faehling, M. | Griesinger, F. | Majem, M. | González Larriba, J.L. | Provencio Pulla, M. | Vervita, K. | Roschitzki-Voser, H. | Ruepp, B. | Mitchell, P. | Stahel, R.A. | Le Pechoux, C. | de Ruysscher, D. | Stahel, R. | Hiltbrunner, A. | Pardo-Contreras, M. | Gasca-Ruchti, A. | Giacomelli, N. | Kammler, R. | Marti, N. | Pfister, R. | Piguet, A.C. | Roux, S. | Troesch, S. | Schneider, M. | Schweri, R. | Zigomo, I. | Tsourti, Z. | Zygoura, P. | Tsouprou, S. | Kassapian, M. | Dimopoulou, G. | Andriakopoulou, C. | Morin, F. | Amour, E. | Mariaule, G. | Archirel, N. | Fernandez, M. | Pereira, E. | Benito, L. | Lopez, K. | Hernández, A. | Chinchen, S. | Jurkovic, H. | Livingstone, A. | Mitchell, J. | Walker, M. | Ng, S. | Steer, C. | Briscoe, K. | Saqib, A. | Abdi, E. | Houghton, B. | O’byrne, K. | Chittajallu, B.R. | Hughes, B.G. | Black, A. | Werner, H. | Zalcman, G. | Vaylet, F. | Merle, P. | Monnet, I. | Girard, N. | Souquet, P.-J. | Barlesi, F. | Debieuvre, D. | Senellart, H. | Poudenx, M. | Dixmier, A. | Pouessel, D. | Cadranel, J. | Lena, H. | Quoix, E. | Friard, S. | Audigier-Valette, C. | Pichon, E. | Kokowski, K. | Kirchen, H. | Tufman, A. | De-Colle, C. | de Langen, J. | Insa, A. | Massutí, B. | Pulla, M.P. | Aix, S.P. | Villanueva, N. | Vivanco, G.L. | Franks, K. | Califano, R.

Edité par CCSD ; Elsevier -

International audience

Consulter en ligne

Suggestions

Du même auteur

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Archive ouverte | Molinier, O. | CCSD

International audience. Background: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) is currently the standard of care in patients ...

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer

Archive ouverte | Quoix, E. | CCSD

International audience. There is no dedicated study on second-line treatment for elderly patients with advanced nonsmall cell lung cancer (NSCLC). We report the results on second-line erlotinib therapy from our prev...

LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.

Archive ouverte | Zalcman, G. | CCSD

International audience

Chargement des enrichissements...